Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) EBITDA Margin (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed EBITDA Margin for 2 consecutive years, with 652.77% as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 652.77% in Q2 2025 year-over-year; TTM through Sep 2025 was 3452.77%, a N/A change, with the full-year FY2024 number at 478.29%, changed N/A from a year prior.
  • EBITDA Margin was 652.77% for Q2 2025 at Pyxis Oncology, down from 20.93% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 20.93% in Q1 2024 to a low of 652.77% in Q2 2025.